The future of cancer treatment lies in targeted therapies. That oft-repeated phrase of the last few years comes with a warning: watch out for drug resistance. A new mathematical model explores how combinations of drugs could keep resistance at bay.
References
Ho, D.D. et al. Nature 373, 123–126 (1995).
Wei, X. et al. Nature 373, 117–122 (1995).
Sawyers, C. Nature 432, 294–297 (2004).
Komarova, N.L. & Wodarz, D. Proc. Natl. Acad. Sci. USA 102, 9714–9719 (2005).
Bonhoeffer, S. & Nowak, M.A. Proc. Biol. Sci. 264, 631–637 (1997).
Roche-Lestienne, C., Lai, J.L., Darre, S., Facon, T. & Preudhomme, C. N. Engl. J. Med. 348, 2265–2266 (2003).
Shah, N.P. et al. Cancer Cell 2, 117–125 (2002).
Iwasa, Y., Michor, F. & Nowak, M.A. Proc. Biol. Sci. 270, 2573–2578 (2003).
Kunkel, T.A. & Bebenek, K. Annu. Rev. Biochem. 69, 497–529 (2000).
Stephens, P. et al. Nat. Genet. 37, 590–592 (2005).
Shah, N.P. et al. Science 305, 399–401 (2004).
Burgess, M.R., Skaggs, B.J., Shah, N.P., Lee, F.Y. & Sawyers, C.L. Proc. Natl. Acad. Sci. USA 102, 3395–3400 (2005).
Gumireddy, K. et al. Proc. Natl. Acad. Sci. USA 102, 1992–1997 (2005).
Carter, T.A. et al. Proc. Natl. Acad. Sci. USA 102, 11011–11016 (2005).
Michor, F. et al. Nature 435, 1267–1270 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sawyers, C. Calculated resistance in cancer. Nat Med 11, 824–825 (2005). https://doi.org/10.1038/nm0805-824
Issue Date:
DOI: https://doi.org/10.1038/nm0805-824
- Springer Nature America, Inc.
This article is cited by
-
Preclinical targeting of NF-κB and FLT3 pathways in AML cells
Leukemia (2008)
-
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
Nature Reviews Drug Discovery (2007)
-
AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells
Leukemia (2007)
-
An increase in cell number at completion of therapy may develop as an indicator of early relapse
Journal of Cancer Research and Clinical Oncology (2007)